Medtronic plc (MDT) : 21 analysts are covering Medtronic plc (MDT) and their average rating on the stock is 1.83, which is read as a Buy. 12 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Medtronic plc (MDT) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Medtronic plc (MDT) stock is expected to deviate a maximum of $11.28 from the average target price of $91.71 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $104 and the most muted being $56.
For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Jefferies maintains its rating on Medtronic plc (NYSE:MDT).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies raises the new price target from $93 per share to $100 per share. The rating by the firm was issued on August 26, 2016.
Medtronic plc (NYSE:MDT): stock was range-bound between the intraday low of $85.99 and the intraday high of $87.1 after having opened at $86.89 on Wednesdays session. The stock finally closed in the red at $86.89, a loss of -1.17%. The stock remained in the red for the whole trading day. The total traded volume was 4,756,536 shares. The stock failed to cross $87.1 in Wednesdays trading. The stocks closing price on Thursday was $87.17.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.